Analyst Price Target is $46.00
▲ +7.00% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Bicycle Therapeutics in the last 3 months. The average price target is $46.00, with a high forecast of $58.00 and a low forecast of $36.00. The average price target represents a 7.00% upside from the last price of $42.99.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in Bicycle Therapeutics. This Buy consensus rating has held steady for over two years.
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.